Search Results
Your search for ,are matches 22257 pages
Showing 101 - 150NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress
The biennial World Cancer Congress, organized by the Union for International Cancer Control (UICC), is the leading international conference on cancer control, bringing together researchers, clinicians, advocates, policymakers, and people with lived experience from more than 120 countries. Two...
Depression Increases Cancer-Specific Mortality Risks in Common Cancers
Depression in patients with cancer may be associated with a higher mortality risk, according to findings from a large SEER-Medicare analysis presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 195). The analysis found that psychotherapy soon after...
Real-World Data Indicate Lower Adherence Rates for Breast Cancer Endocrine Therapy When Radiation Therapy Is Omitted
Many patients with early-stage breast cancer do not consistently maintain the long-term hormone therapy prescribed after lumpectomy, a large U.S. insurance claims analysis indicates. Findings provide important real-world context for treatment approaches that consider omitting radiation therapy,...
Ultra–Low-Dose Radiation Therapy May Relieve Bone Pain From Multiple Myeloma
A short course of ultra–low-dose radiation therapy relieved painful bone lesions from multiple myeloma for patients in a multi-institutional phase II clinical trial. The findings suggest that a lower-intensity approach could help ease patients’ pain without interrupting other treatment and with few ...
Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology
Cancer remains a dominant driver of morbidity and mortality globally and in the United States and continues to impose a substantial and evolving public health burden. Although age-adjusted cancer mortality has declined steadily for more than 3 decades, demographic aging and population growth have...
Short-Course SBRT Better Preserves Physical Function Before Pancreatic Cancer Surgery
Patients preparing for pancreatic cancer surgery maintained better physical function and experienced less fatigue with 5 treatments of stereotactic body radiation therapy (SBRT) than with 28 treatments of conventional radiation therapy given with chemotherapy, according to findings of a randomized...
New Prognostic Model May Improve Risk Classification in Metastatic Clear Cell RCC
A new prognostic model developed for the checkpoint inhibitor era showed better discrimination of survival outcomes in patients with previously untreated metastatic clear cell renal cell carcinoma (RCC) than the widely used International Metastatic RCC Database Consortium (IMDC) model. The...
Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma
Longer follow-up from a phase I trial of intracerebroventricular bivalent CAR T-cell therapy in recurrent glioblastoma showed no long-term or delayed-onset toxicities, with a median overall survival of 12.0 months, according to updated data presented at the 2026 ASCO Annual Meeting. The...
Building Momentum: ASCO’s Geriatric Oncology CoP
The ASCO Geriatric Oncology Community of Practice (geriatric oncology CoP) convened for its first in-person meeting at McCormick Place in Chicago in May 2026. Since its inception in 2022, the geriatric oncology CoP has brought together clinicians, researchers, trainees, and patient advocates...
I Wasn’t Expecting Cancer at 22
Before I was diagnosed with advanced stage ovarian ependymoma, in 2025, when I was just 22, I didn’t know anything about cancer. I knew a few older adults who had had cancer, but that was the extent of my knowledge about the disease. Even to this day, I’m not sure I’ve completely wrapped my head...
Guideline Update Recommends Tailoring Breast Cancer Surveillance Based on Recurrence Risk
ASCO has published a guideline update offering clinicians new recommendations for breast cancer follow-up and surveillance after primary treatment.1 For this patient population, determining the optimal frequency and timing of visits can be a challenge, according to Expert Panel Co-Chair Maryam...
Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors
The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
A multimodal artificial intelligence (AI) model incorporating multiscale histopathology features was able to predict recurrence risk in patients with early-stage hormone receptor–positive and HER2-negative breast cancer more accurately than the 21-gene recurrence score, Oncotype DX, according to...
How One Nonprofit Is Providing Access to a Discontinued Investigational Drug for Children With a Rare Form of AML
Blood Cancer United (formerly the Leukemia & Lymphoma Society) recently announced it had acquired the remaining supply and rights to the investigational agent luveltamab tazevibulin, an antibody-drug conjugate targeting the folate receptor-1 alpha (FOLR1) molecule, from the drug’s manufacturer, ...
As AI Advances, How Will the Clinician’s Role Change?
Peter Clardy, MD, of Google for Health, described a fundamental challenge facing clinicians in the artificial intelligence (AI) era: AI capabilities are advancing rapidly at the same time clinicians are being asked to make decisions based on an ever-expanding volume of information. In oncology...
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
New updates to the College of American Pathologists’ (CAP) Cancer Protocols will affect breast cancer biomarker reporting and molecular testing for gastrointestinal stromal tumors (GISTs), reflecting advances in precision oncology and laboratory accreditation. The updates are part of revisions to...
Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC
Daraxonrasib produced responses in more than 30% of patients with previously treated advanced RAS-mutant non–small cell lung cancer (NSCLC), with activity observed across multiple RAS mutations in a phase I/II study. Results from Kathryn C. Arbour, MD, David S. Hong, MD, and colleagues were...
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Adding venetoclax to dose-adjusted EPOCH-R (DA-EPOCH-R) did not improve progression-free survival and resulted in excess toxicity and mortality among patients with newly diagnosed double-hit lymphoma, prompting early closure of the double-hit lymphoma cohort of the randomized ALLIANCE A051701...
Neoadjuvant Anbenitamab/Chemotherapy Combination Improves Response in ERBB2-Positive Breast Cancer
Neoadjuvant treatment with the ERBB2-biparatopic antibody anbenitamab plus a solvent-free albumin-bound docetaxel formulation (HB1801) significantly improved total pathologic complete response vs conventional therapy with trastuzumab plus pertuzumab and a taxane (THP) in patients with early or...
Germline EGFR T790M Associated With Significant Lung Cancer Risk
Researchers have found a significantly increased risk of lung cancer in individuals with an EGFR T790M germline variant, about 25 times higher than in noncarriers, according to study findings published in Science. “Today, lung cancer screening is driven almost entirely by smoking history,” said...
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
Researchers have identified varying clinicopathologic characteristics and outcomes between patients with non–small cell lung cancer (NSCLC) and class II and III BRAF mutations, according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World...
ASCO Breakthrough Studies Target Supportive Care Problems That Can Derail Treatment
Three studies presented at the 2026 ASCO Breakthrough conference in Singapore focused on problems that can derail cancer care even when treatment is otherwise on track: nausea after starting morphine, continued smoking after a cancer diagnosis, and unrecognized frailty in older adults. Although the ...
AACR Releases Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 16th edition of its annual Cancer Progress Report. This comprehensive report provides current data on cancer incidence, mortality, and survivorship. It also outlines how basic, translational, and clinical cancer research and...
Plant-Based Diet Linked to Lower Risk of Prostate Cancer Progression on Active Surveillance
For many men with low-risk prostate cancer, active surveillance means living with cancer while delaying—or potentially avoiding—surgery or radiation therapy. It also leaves many patients asking what they can do beyond “wait and watch.” Findings presented at the 2026 American Urological Association...
ASTRO Issues Its First Clinical Guideline on Radiation Therapy for Bladder Cancer
For appropriately selected patients with muscle-invasive bladder cancer, bladder preservation can be a curative treatment option, according to a new clinical guideline from the American Society for Radiation Oncology (ASTRO). The recommendations support trimodal therapy (maximal transurethral...
Losing Weight and Breast Cancer Risk? The GLP-1 RA Question
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity and diabetes has sparked interest in their potential effects on breast cancer risk and outcomes. At the 2026 ASCO Annual Meeting, investigators presented several observational studies examining the relationship...
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including oral triple metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from...
Alcohol-Attributable Cancer Deaths More Than Double in the United States
Cancer mortality associated with alcohol use has risen in the United States, disproportionately affecting males and adults aged at least 55 years, according to a population-based observational trend analysis published by Jani et al in The Lancet Regional Health – Americas. “Our findings highlight...
Azacitidine/Venetoclax Improves Event-Free Survival in Fit Patients With AML
Azacitidine plus venetoclax significantly prolonged event-free survival compared with intensive induction chemotherapy in previously untreated patients with acute myeloid leukemia (AML) who were eligible for induction therapy. Results of the randomized phase II PARADIGM trial, led by Fathi et al,...
AI’s Evolving Role in Clinical Care Enterprise-Wide
Artificial intelligence could reshape health care by reducing administrative work, helping physicians identify and manage disease, and extending care beyond traditional clinical settings—potentially allowing caregivers to focus more on patient care and human interaction, according to Cleveland...
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Trastuzumab deruxtecan significantly improved progression-free survival over pembrolizumab plus platinum-based chemotherapy for patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC) who were being treated in the first-line setting, according to phase III DESTINY-Lung04 ...
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
The National Comprehensive Cancer Network® (NCCN®) has released a new resource to help patients and caregivers understand how to tailor cancer care for aging populations. “The medical advances we’ve seen in cardiology and infectious disease are a huge triumph; because we are better at treating...
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
In the large, platform-based, independent validation study CATALINA, published by Dixon-Douglas et al in The Lancet Oncology, two artificial intelligence (AI)-derived computational tumor-infiltrating lymphocyte (cTIL) models, which were deployed without retraining or modification, provided...
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
This September, in honor of Prostate Cancer Awareness Month, the American Cancer Society is encouraging men to discuss their risks of prostate cancer with their doctors and the possibility of screening. The American Cancer Society noted that cases of prostate cancer have continued to increase by...
Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC
Adjuvant alectinib was associated with early improvements in health-related quality of life that were maintained over 2 years of treatment in patients with resected ALK-positive non–small cell lung cancer (NSCLC). The new analysis of the phase III ALINA trial, reported by Dziadziuszko et al in The...
FDA Approves Topical Photodynamic Therapy for Superficial BCC
Today, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for aminolevulinic acid hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic therapy (PDT) using the BF-RhodoLED lamp series, for the treatment of superficial basal cell carcinoma...
New NCCN Survey Highlights Persistent Cancer Drug Shortages
The National Comprehensive Cancer Network® (NCCN®) recently published updated data on the current impact of generic cancer medication shortages in the United States. The data come from survey responses from pharmacy directors and other clinical and administrative leadership at NCCN Member...
What Constitutes Clinical Expertise in an AI-Enabled Era?
In a keynote speech delivered recently at Cleveland Clinic's A.I. Summit for Healthcare Professionals, Peter Clardy, MD, of Google for Health, made the case that the rapid evolution currently underway in AI is unfolding as clinicians are also being asked to make decisions from an ever-expanding...
Surviving Cancer Put Me On a Career Path in Cancer Research
I was just 24 and in seemingly perfect health when I began experiencing unexplained abdominal pain so excruciating, even daily doses of pain medication failed to provide relief. I was a senior in college and had enrolled in a summer internship program at the University of California, Davis, when my ...
20th Annual Award for Leadership in Personalized Medicine
The Personalized Medicine Coalition (PMC), a nonprofit organization dedicated to advancing personalized medicine, recently announced that physician-scientist Norman E. “Ned” Sharpless, MD, has been selected as the recipient of the 20th Annual Award for Leadership in Personalized Medicine,...
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical feasibility penalty in patients with microsatellite-stable (MSS) locally advanced rectal cancer,...
‘Save Research’ Campaign Champions Federal Funding
ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline. “The People Behind the Progress,” an ASCO social media series, features members sharing how federal cancer research has...
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) recently approved daraxonrasib, (Rasonque), a multiselective RAS(ON) inhibitor, for treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. ...
Structured Exercise After Adjuvant Chemotherapy for Colon Cancer Improves Survival and Saves Costs
A structured exercise program after adjuvant chemotherapy for colon cancer improved survival and saved money. In a preplanned cost-utility analysis of the phase III CHALLENGE trial, presented at the 2026 ASCO Annual Meeting1 and published simultaneously in the Journal of Clinical Oncology,2 the...
Long-Term Trial Supports Selective Use of Extended Pelvic Lymph Node Dissection in High-Grade Prostate Cancer
Extended pelvic lymph node dissection has long been used during radical prostatectomy to improve staging in men with higher-risk prostate cancer. Whether the more extensive operation also improves cancer outcomes has been less clear. New long-term randomized data presented at the 2026 American...
NSCLC: FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
Robert A. Kyle, MD, Myeloma Expert, Dies at 98
The International Myeloma Foundation (IMF) shared news of the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Duane A. Mitchell, MD, PhD, Named Director of the UF Health Cancer Institute
The University of Florida has selected Duane A. Mitchell, MD, PhD, as the next Director of the UF Health Cancer Institute. Dr. Mitchell, the Phyllis Kottler Friedman Professor in the Department of Neurosurgery, assumes the role September 21 at a pivotal moment for the institute, which earned...
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
In addition to searching for breast cancer, artificial intelligence (AI) used in mammography reads may help to detect common cardiovascular diseases, according to study findings presented at the ESC Congress 2026. “Because mammography is already widely used, analyzing the same images for...
Prostate Cancer: Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
A set of uncontrolled, modifiable cardiovascular risk factors may help identify a subgroup of patients with prostate cancer who could benefit from additional cardiovascular care, according to findings published in JACC: CardioOncology and presented at the ESC Congress 2026. “The major findings...
